公开(公告)号：WO2011130669A1

公开(公告)日：2011-10-20

申请号：PCT/US2011/032736

申请日：2011-04-15

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE S.A. ,  AKONUR, Alp ,  LEYPOLDT, John, Kenneth ,  LO, Ying-Cheng ,  AGAR, Baris, Ugar

Inventor： AKONUR, Alp ,  LEYPOLDT, John, Kenneth ,  LO, Ying-Cheng ,  AGAR, Baris, Ugar

IPC: G06F19/00 ,  A61M1/14

CPC classification number: A61M1/16 ,  A61M1/1613 ,  A61M1/1619 ,  A61M2202/0498 ,  A61M2205/15 ,  A61M2205/505 ,  A61M2205/52

Abstract: A renal failure blood therapy system includes: (i) a renal failure blood therapy machine; (ii) a therapy prescription for a patient treated by the renal failure blood therapy machine to remove a solute from the patient's blood; (iii) a test including multiple blood samples taken at multiple times during a test therapy to determine concentration levels of the solute at each of the multiple times; and (iv) a device programmed to use a kinetic model for the solute in a first instance with at least one of the concentration levels of the solute to estimate at least one estimated patient parameter. The device is further programmed to enable a user to determine at least one of a therapy duration, a therapy frequency, a dialysate flowrate or a blood flowrate for the therapy prescription.

Abstract translation: 肾衰竭血液治疗系统包括：（i）肾衰竭血液治疗机; （ii）由肾衰竭血液治疗机治疗的患者的治疗处方，以从患者血液中除去溶质; （iii）包括在测试治疗期间多次采集的多个血液样本的测试以确定多次中的每一次的溶质的浓度水平; 以及（iv）被编程为在第一种情况下使用溶质的动力学模型的装置，其中至少一个所述溶质的浓度水平估计至少一个估计的患者参数。 该装置还被编程为使得用户能够确定用于治疗处方的治疗持续时间，治疗频率，透析液流量或血液流速中的至少一个。

公开(公告)号：WO2012129017A1

公开(公告)日：2012-09-27

申请号：PCT/US2012/028999

申请日：2012-03-14

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE S.A. ,  LEYPOLDT, John Kenneth ,  HOLMES, Clifford J. ,  KAROOR, Sujatha ,  HOFF, Catherine M. ,  MARTIS, Leo ,  TANDON, Rahul

Inventor： LEYPOLDT, John Kenneth ,  HOLMES, Clifford J. ,  KAROOR, Sujatha ,  HOFF, Catherine M. ,  MARTIS, Leo ,  TANDON, Rahul

IPC: A61K31/716 ,  A61K31/717 ,  A61K31/718 ,  C08L3/00 ,  A61P13/00

CPC classification number: A61K31/717 ,  A61K31/716 ,  A61K31/718 ,  C08L3/02

Abstract: Peritoneal dialysis solutions including a glucose polymer and methods of using the dialysis solutions are disclosed herein. In a general embodiment, the peritoneal dialysis solution includes a glucose polymer in an amount to provide an increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed compared to conventional dialysis solutions containing icodextrin as the active pharmaceutical ingredient. The increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed is obtained by providing specific combinations of weight-average molecular weight, polydispersity index and concentration of the glucose polymer in the dialysis solution.

Abstract translation: 本文公开了包括葡萄糖聚合物的腹膜透析溶液和使用透析溶液的方法。 在一般实施方案中，腹膜透析溶液包含葡萄糖聚合物，其含量与给定量的碳水化合物相比提供了增加的超滤流体体积，与常规含有作为活性药物成分的伊曲诺白蛋白的透析溶液相比。 通过提供透析溶液中葡萄糖聚合物的重均分子量，多分散指数和浓度的特定组合，可以获得给定量的碳水化合物吸收增加的超滤液体积。

公开(公告)号：WO2011130668A1

公开(公告)日：2011-10-20

申请号：PCT/US2011/032735

申请日：2011-04-15

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE S.A. ,  AKONUR, Alp ,  LEYPOLDT, John Kenneth ,  LO, Ying-Cheng ,  AGAR, Baris Ugar

Inventor： AKONUR, Alp ,  LEYPOLDT, John Kenneth ,  LO, Ying-Cheng ,  AGAR, Baris Ugar

IPC: G06F19/00

CPC classification number: A61M1/16 ,  A61M1/1613 ,  A61M1/1619 ,  A61M2202/0498 ,  A61M2205/15 ,  A61M2205/505 ,  A61M2205/52

Abstract: A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.

Abstract translation: 在血液透析期间预测患者血清磷浓度的方法包括测量血液透析治疗会话时间的患者的血清磷浓度，以及通过初始血液透析期间患者的透析前和透析后体重之间的差异计算的超滤率 治疗时间除以治疗会话的总治疗时间，并估计患者的磷的移动清除率和磷酸盐的透析前分布体积。 然后可以在任何血液透析治疗期间的任何时间预测患者的血清磷浓度，其中估计磷移动清除率和患者的磷的透析前分布体积。